Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a derivative of the endogenous peptide tuftsin. Registered in Russia for the treatment of anxiety and phobic disorders, Selank occupies a unique position in the nootropic peptide space: it reduces anxiety without sedation, dependency, or the cognitive blunting associated with benzodiazepines. For researchers studying anxiolytic mechanisms or stress resilience, it's one of the most pharmacologically interesting tools available.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Selank primarily reduces anxiety through GABA-A receptor modulation and enkephalin stabilisation. Unlike benzodiazepines, it produces calming effects without sedation, cognitive blunting, or dependency risk. Additional effects include improved mood, stress resilience, and mild cognitive enhancement.
How Does Selank Work?
Selank's primary anxiolytic effect involves modulation of GABA-A receptors — the same receptors targeted by benzodiazepines. However, Selank acts as a modulator rather than a direct agonist, producing calming effects without the receptor downregulation, tolerance, and withdrawal that characterise benzodiazepine dependence.
A second key mechanism involves stabilisation of enkephalins — endogenous opioid peptides that regulate mood, pain, and stress response. Selank inhibits enkephalin-degrading enzymes, prolonging the activity of these natural mood-stabilising compounds. This enkephalin stabilisation contributes to Selank's reported improvements in emotional resilience and stress tolerance.
Selank also modulates serotonin metabolism and has shown BDNF upregulation similar to Semax, though less pronounced. The net pharmacological profile — GABA modulation + enkephalin stabilisation + serotonin effects + mild BDNF — explains why users report reduced anxiety, improved mood, and cognitive clarity simultaneously.
Clinical Background and Evidence
Selank was developed and clinically tested in Russia through the 1990s and 2000s, with the Institute of Molecular Genetics leading its research program. It received regulatory approval in Russia for generalised anxiety disorder and neurasthenia, giving it a clinical evidence base that most Western research peptides lack.
Published human clinical data shows Selank reducing anxiety scores on standard psychometric scales (Hamilton Anxiety Rating Scale) compared to placebo, with an effect size comparable to benzodiazepines in mild-to-moderate anxiety — but without sedation or memory impairment. A notable finding was improvement in learning and memory alongside anxiety reduction, which is the opposite of what benzodiazepines typically produce.
In animal models, Selank demonstrated antidepressant effects, improved immune function (via tuftsin-related immunomodulatory activity), and neuroprotective effects in stress models. The immunomodulatory angle is less commonly discussed but mechanistically interesting — tuftsin, Selank's parent compound, is a natural immune regulator.
What Is the Recommended Selank Dosage?
| Form | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Selank standard | 250–500 mcg | Intranasal | 1–3x daily | Most common protocol |
| NA-Selank | 100–250 mcg | Intranasal | 1–2x daily | More potent acetylated form |
| Selank injectable | 250 mcg | SubQ | 1–2x daily | Less common than intranasal |
| Acute anxiety protocol | 500 mcg | Intranasal | As needed | For situational anxiety |
Side Effects and Stacking
Selank has one of the most benign side effect profiles of any nootropic peptide. Most research subjects report essentially no negative effects at standard doses — this is consistent with its clinical trial data where side effects were minimal compared to benzodiazepine comparators.
**Mild sedation** is occasionally reported at higher doses (500+ mcg), particularly in individuals sensitive to GABAergic compounds. Most users describe it as relaxed-but-clear rather than sedated.
**No dependency or withdrawal** has been documented in clinical studies or reported meaningfully in community use — the key differentiator from benzodiazepines. This is attributed to Selank's modulator (rather than direct agonist) activity at GABA-A.
**Stacking with Semax:** The most common nootropic peptide stack. Semax provides cognitive enhancement and mild stimulation; Selank provides anxiety reduction and social ease. Together they cover the focus-plus-calm profile that neither achieves alone. Typical protocol: Semax in the morning, Selank 30–60 minutes before high-stress situations or as needed throughout the day.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Selank primarily reduces anxiety through GABA-A receptor modulation and enkephalin stabilisation. Unlike benzodiazepines, it produces calming effects without sedation, cognitive blunting, or dependency risk. Additional effects include improved mood, stress resilience, and mild cognitive enhancement. It is registered as an anxiolytic medication in Russia.
No addiction or physical dependence has been documented in Selank's clinical research or community use. This distinguishes it clearly from benzodiazepines, which act on the same receptor class but cause tolerance and withdrawal through direct agonism. Selank's modulator mechanism avoids receptor downregulation.
They serve different primary purposes. Selank is best for anxiety reduction, stress resilience, and calm focus. Semax is best for cognitive enhancement, memory, and mental sharpness. They're complementary rather than competing — the most common protocol stacks both. If choosing one: use Selank for anxiety-dominant issues, Semax for cognition-dominant goals.
Most protocols use Selank daily for 2–4 week cycles. The lack of documented tolerance development makes continuous use theoretically safer than many anxiolytics, but cycling is still practiced as standard precaution. Many users report no diminishing effect over weeks of daily use.
Selank is reconstituted in bacteriostatic water or sterile saline and administered using a nasal atomizer or sterile dropper. Typical volume is 25–50 mcL per nostril. The olfactory route provides direct CNS delivery bypassing the blood-brain barrier. Avoid blowing nose for 10 minutes after dosing for maximum absorption.
Selank produces calm and reduced anxiety without meaningful sedation in most users at standard doses (250–500 mcg). This is one of its key advantages over benzodiazepines. At higher doses some users report mild relaxation that could interfere with tasks requiring alertness. Most describe the experience as anxiolysis-without-sedation.